• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Killefer Nancy converted options into 11,928 shares, increasing direct ownership by 49% to 36,089 units (SEC Form 4)

    5/22/25 5:04:32 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CERT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Killefer Nancy

    (Last) (First) (Middle)
    C/O CERRTARA, INC.
    4 RADNOR CORPORATE CENTER, SUITE 350

    (Street)
    RADNOR PA 19087

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Certara, Inc. [ CERT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/21/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/21/2025 M 11,928 A $0(1) 36,089 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 05/21/2025 M 11,928 (1) (1) Common Stock 11,928 $0 0 D
    Restricted Stock Units (2) 05/21/2025 A 15,757 (2) (2) Common Stock 15,757 $0 15,757 D
    Explanation of Responses:
    1. Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting.
    2. Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.
    /s/ Daniel Corcoran, as Attorney-in-Fact for Nancy Killefer 05/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CERT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CERT

    DatePrice TargetRatingAnalyst
    11/21/2025$10.00Buy
    Rothschild & Co Redburn
    11/13/2025$9.00Market Perform
    BMO Capital Markets
    9/29/2025$16.00Buy
    Craig Hallum
    7/3/2025$16.00Equal-Weight
    Morgan Stanley
    5/8/2025$14.00Equal Weight → Overweight
    Barclays
    2/27/2025$16.00Buy
    TD Cowen
    9/27/2024$16.00Neutral → Buy
    UBS
    4/10/2024$23.00Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $CERT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Feehery William F bought $200,000 worth of shares (24,096 units at $8.30), increasing direct ownership by 1% to 2,360,769 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    11/12/25 4:44:55 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    SEC Filings

    View All

    Certara Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Certara, Inc. (0001827090) (Filer)

    12/11/25 6:00:54 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Certara Inc.

    SCHEDULE 13G/A - Certara, Inc. (0001827090) (Subject)

    11/25/25 3:36:45 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SCHEDULE 13G filed by Certara Inc.

    SCHEDULE 13G - Certara, Inc. (0001827090) (Subject)

    11/13/25 5:32:49 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rothschild & Co Redburn initiated coverage on Certara with a new price target

    Rothschild & Co Redburn initiated coverage of Certara with a rating of Buy and set a new price target of $10.00

    11/21/25 8:08:25 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    BMO Capital Markets initiated coverage on Certara with a new price target

    BMO Capital Markets initiated coverage of Certara with a rating of Market Perform and set a new price target of $9.00

    11/13/25 9:12:36 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Craig Hallum initiated coverage on Certara with a new price target

    Craig Hallum initiated coverage of Certara with a rating of Buy and set a new price target of $16.00

    9/29/25 9:57:26 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Feehery William F bought $200,000 worth of shares (24,096 units at $8.30), increasing direct ownership by 1% to 2,360,769 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    11/12/25 4:44:55 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    PRESIDENT, CHIEF COMMERCAL OFF Pedersen Leif E sold $559,366 worth of shares (51,224 units at $10.92), decreasing direct ownership by 41% to 73,979 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    9/11/25 4:47:56 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Chief Human Resources Officer Anhalt Rona converted options into 7,146 shares and covered exercise/tax liability with 1,965 shares (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    6/2/25 4:58:36 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave

    Issued on behalf of Aleen Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies are cutting drug discovery timelines by 30% or more through AI models that predict molecular behavior before researchers invest months in testing, marking a fundamental shift from traditional trial-and-error approaches to computational creation of biological solutions[1]. The generative AI healthcare market is projected to surge from $2.64B in 2025 to $39.70B by 2034, reflecting the technology's expansion from simple data analysis to active creation and interpretation of therapeutic compounds[2]. This Platform-First revolution is extending rapidly into c

    12/12/25 10:15:00 AM ET
    $ABSI
    $AMZN
    $CERT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Catalog/Specialty Distribution
    Consumer Discretionary

    Healthcare AI Exits Pilot Phase, Enters Production Deployment

    VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Healthcare organizations are setting the pace for enterprise AI adoption as operational automation moves from experimentation to production scale across hospital systems[1]. The shift reflects a fundamental change in how healthcare leaders view AI technology, with deployment projected to expand the global healthcare AI market from $17.2 billion in 2025 to $77.2 billion by 2035[2]. Five publicly traded companies are positioned at the intersection of this operational transformation, delivering infrastructure that turns AI capabilities into measurable workflow improvements and financial returns

    12/12/25 9:59:27 AM ET
    $CERT
    $CTSH
    $DOCS
    Computer Software: Prepackaged Software
    Technology
    EDP Services
    Medical Specialities

    Certara Appoints Jon Resnick as Chief Executive Officer

    Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara's Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a g

    12/11/25 6:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Leadership Updates

    Live Leadership Updates

    View All

    Certara Appoints Jon Resnick as Chief Executive Officer

    Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara's Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a g

    12/11/25 6:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

    RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology. Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data

    7/31/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

    RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

    3/5/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Financials

    Live finance-specific insights

    View All

    Certara Reports Third Quarter 2025 Financial Results

    RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Services revenue was $60.8 million, compared to $58.9 million in the third quarter of 2024, representing growth of 3%. Net income was $1.5 million, compared to a net loss of $1.4 million in the third quarter of 2024, representing

    11/6/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

    RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulation softw

    10/10/25 8:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Reports Second Quarter 2025 Financial Results

    RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million, compared to $38.2 million in the second quarter of 2024, representing growth of 22%.Service revenue was $57.9 million, compared to $55.1 million in the second quarter of 2024, representing growth of 5%. Net loss was $2.0 million, compared to a net loss of $12.6 million in the second quarter of 2024, repr

    8/6/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Certara Inc.

    SC 13G - Certara, Inc. (0001827090) (Subject)

    11/14/24 8:38:56 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Certara Inc.

    SC 13G/A - Certara, Inc. (0001827090) (Subject)

    10/4/24 10:25:50 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Certara Inc. (Amendment)

    SC 13G/A - Certara, Inc. (0001827090) (Subject)

    2/13/24 5:01:03 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology